Menu Search
Equities

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

2TZ:STU

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Actions
  • Price (EUR)2.10
  • Today's Change-0.044 / -2.03%
  • Shares traded0.00
  • 1 Year change+34.52%
  • Beta--
Data delayed at least 15 minutes, as of Nov 05 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, formerly Tianjin Zhongxin Pharmaceutical Group Co Ltd, is a China-based company mainly engaged in the production, operation and scientific research of green traditional Chinese medicine. The Company's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The Company's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.

  • Revenue in USD (TTM)1.14bn
  • Net income in USD129.86m
  • Incorporated1981
  • Employees11.00k
  • Location
    Tianjin Pharmaceutical Da Ren Tang Group Corp LtdNo. 17, Baidi Road, Nankai DistrictTIANJIN 300193ChinaCHN
  • Phone+86 2 227020892
  • Fax+86 2 227020892
  • Websitehttps://www.jydrt.com.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.